RGEN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

118.790

Open

118.790

VWAP

116.87

Vol

159.17K

Mkt Cap

6.67B

Low

115.310

Amount

18.60M

EV/EBITDA(TTM)

43.73

Total Shares

56.40M

6.45B

EV/OCF(TTM)

54.91

P/S(TTM)

9.07

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.

Events Timeline

(ET)

2026-04-17

07:40:00

Repligen Opens Training & Innovation Center in the Netherlands

News

9.5

04-30CNBC

Next Week's Earnings Season to Feature Multiple Companies

6.0

04-17CNBC

Latest Ratings and Outlook from Wall Street

4.5

04-17Yahoo Finance

Repligen Opens New Training & Innovation Center in Breda, Netherlands

7.5

04-17Newsfilter

Repligen Opens New Innovation Center in the Netherlands

6.5

03-06Fool

Brown Capital Management Sells AppFolio Shares Worth $45.11 Million

2.0

03-06NASDAQ.COM

Brown Capital Sells AppFolio Shares Worth $45.11 Million

12 Analyst Rating

Wall Street analysts forecast RGEN stock price to rise

9 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

165.00

Averages

189.00

High

207.00

Current: 0.000

Low

165.00

Averages

189.00

High

207.00

Canaccord

Hold

downgrade

$165 -> $145

AI Analysis

2026-04-20

Reason

Canaccord

Price Target

$165 -> $145

AI Analysis

2026-04-20

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Repligen to $145 from $165 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results and they believe the shares could be attractive with continued momentum or additional material share price pullback. They are optimistic regarding the tools and diagnostics sector from the company-specific and macro perspectives.

Rothschild & Co Redburn

Buy

initiated

$160

2026-04-17

Reason

Rothschild & Co Redburn

Price Target

$160

2026-04-17

initiated

Buy

Reason

Rothschild & Co Redburn initiated coverage of Repligen with a Buy rating and $160 price target. The firm says Repligen is a pure-play bioprocessing company and leader in continuous manufacturing. The stock's premium valuation is warranted given the company's "sector-leading" mid-term revenue and adjusted earnings outlooks of 15% and 29% respectively, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGEN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Repligen Corp (RGEN.O) is 59.52, compared to its 5-year average forward P/E of 83.92. For a more detailed relative valuation and DCF analysis to assess Repligen Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

83.92

Current PE

59.52

Overvalued PE

103.38

Undervalued PE

64.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

55.45

Current EV/EBITDA

33.44

Overvalued EV/EBITDA

70.46

Undervalued EV/EBITDA

40.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.26

Current PS

6.71

Overvalued PS

16.62

Undervalued PS

9.90

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

so what Company is best for me

Intellectia · 79 candidates

Price: $5.00 - $400.00Relative Vol: >= 3List Exchange: XNYS, XNAS, XASEOne Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

ITGR

Integer Holdings Corp

3.00B

VERX

Vertex Inc

2.12B

SCHW

Charles Schwab Corp

164.81B

SPHR

Sphere Entertainment Co

3.95B

IRON

Disc Medicine Inc

2.42B

CRI

Carter's Inc

1.55B

stocks that predict to rise in one week

Intellectia · 39 candidates

Market Cap: >= 5.00BPrice: $10.00 - $250.00One Week Rise Prob: >= 72One Week Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

CVE

Cenovus Energy Inc

42.47B

SCHW

Charles Schwab Corp

164.81B

NiSource Inc

22.11B

ATO

Atmos Energy Corp

30.06B

CIGI

Colliers International Group Inc

5.69B

RGEN

Repligen Corp

7.62B

Whales Holding RGEN

Perceptive Advisors LLC

Vestal Point Capital, LP

Blue Whale Capital LLP

Fred Alger Management, LLC

Congress Asset Management Company, LLP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Repligen Corp (RGEN) stock price today?

The current price of RGEN is 116.515 USD — it has decreased -1.52

What is Repligen Corp (RGEN)'s business?

What is the price predicton of RGEN Stock?

Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is189.00 USD with a low forecast of 165.00 USD and a high forecast of 207.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Repligen Corp (RGEN)'s revenue for the last quarter?

Repligen Corp revenue for the last quarter amounts to 197.91M USD, increased 18.12

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

Repligen Corp. EPS for the last quarter amounts to 0.23 USD, decreased -138.33

How many employees does Repligen Corp (RGEN). have?

Repligen Corp (RGEN) has 2000 emplpoyees as of May 01 2026.

What is Repligen Corp (RGEN) market cap?

Today RGEN has the market capitalization of 6.67B USD.

RGEN Overview

RGEN Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding RGEN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Repligen Corp (RGEN) stock price today?

What is Repligen Corp (RGEN)'s business?

What is the price predicton of RGEN Stock?

What is Repligen Corp (RGEN)'s revenue for the last quarter?

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

How many employees does Repligen Corp (RGEN). have?

What is Repligen Corp (RGEN) market cap?